Kala Pharmaceuticals, Inc. (KALA) financial statements (2021 and earlier)

Company profile

Business Address 490 ARSENAL WAY
WATERTOWN, MA 02472
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments15485171115
Cash and cash equivalents7785171115
Short-term investments76   
Receivables1013  
Inventory, net of allowances, customer advances and progress billings554 
Inventory554 
Prepaid expense2210
Other current assets  00
Other undisclosed current assets111 
Total current assets:171105177115
Noncurrent Assets
Inventory, Noncurrent64  
Operating lease, right-of-use asset2830
Property, plant and equipment3321
Restricted cash and investments1213120
Other undisclosed noncurrent assets0 30 
Total noncurrent assets:5049441
TOTAL ASSETS:222154221116
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities2123178
Accounts payable2351
Accrued liabilities1921117
Debt 1 7
Other undisclosed current liabilities2 0 
Total current liabilities:22251714
Noncurrent Liabilities
Long-term debt and lease obligation991009912
Long-term debt, excluding current maturities72717012
Finance lease, liability2729
Capital lease obligations29 
Liabilities, other than long-term debt   0
Other liabilities   0
Total noncurrent liabilities:991009912
Total liabilities:12212511626
Stockholders' equity
Stockholders' equity attributable to parent1003010590
Common stock0000
Additional paid in capital500325306224
Accumulated other comprehensive income0   
Accumulated deficit(400)(295)(201)(134)
Total stockholders' equity:1003010590
TOTAL LIABILITIES AND EQUITY:222154221116

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
Gross profit:66  
Operating expenses(103)(94)(65)(40)
Operating loss:(96)(88)(65)(40)
Nonoperating income
(Investment Income, Nonoperating)
0221
Interest and debt expense(9)(8)(4)(1)
Loss before gain (loss) on sale of properties:(104)(94)(67)(40)
Other undisclosed net loss   (2)
Net loss available to common stockholders, diluted:(104)(94)(67)(42)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
Net loss:(104)(94)(67)(42)
Other comprehensive income0   
Comprehensive loss, net of tax, attributable to parent:(104)(94)(67)(42)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: